1F10, a λ Light Chain Amyloid-Specific Monoclonal Antibody for Targeted Therapy of AL Amyloidosis

The authors aim to develop a targeted therapy for AL amyloidosis by creating 1F10, a high-affinity monoclonal antibody specifically designed to bind to lambda light chain (LC) amyloid fibrils. Unlike previous therapies that failed due to insufficient binding affinity, 1F10 demonstrates superior binding and enhances the clearance of amyloid fibrils in vitro and in vivo, positioning it as a promising immunotherapeutic candidate for patients affected by this condition.